Figure 3.

The association between serum CYR61 and pulmonary NF-κB activation in COPD patients. Lung tissues were collected from COPD patients and controls. Pulmonary NF-κB p65 was detected using IHC. (A,B) Pulmonary NF-κB p65-positive nuclei were compared between COPD patients and control subjects. (A) Three representative pictures: arrows indicate p65-positive nuclei; (B) Quantitative analysis of p65-positive nuclei in COPD patients and controls. (C,D) Pulmonary NF-κB p65-positive nuclei were compared among COPD patients with different levels of CYR61. (C) Three representative pictures: arrows indicate p65-positive nuclei; (D) Quantitative analysis of p65-positive nuclei in COPD patients with different levels of CYR61. All data were represented as means ± S.E.M. (N = 6). *P < 0.05, **P < 0.01.